The graphic illustrates why Novo Nordisk and Eli Lilly will continue dominating the market, with broader competition in the GLP-1 drug race still several years away.

Pipeline expansion has been robust; however, as with all drug development, extended clinical trials, regulatory approval processes, and commercialisation timelines result in a lengthy path to market for weight-loss drugs.